<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC2015052/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Identification of the major human liver cytochrome P450
isoform(s) responsible for the formation of the primary metabolites
of ziprasidone and prediction of possible drug interactions</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC2015052/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions" />
<meta name="citation_authors" content=
"C Prakash, A Kamel, D Cui, R D Whalen, J J Miceli, D Tweedie" />
<meta name="citation_date" content="January 2000" />
<meta name="citation_issue" content="Suppl 1" />
<meta name="citation_volume" content="49" />
<meta name="citation_firstpage" content="35S" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2000.00151.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC2015052/?report=abstract" />
<meta name="citation_pmid" content="10771452" />
<meta name="DC.Title" content=
"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="C Prakash" />
<meta name="DC.Contributor" content="A Kamel" />
<meta name="DC.Contributor" content="D Cui" />
<meta name="DC.Contributor" content="R D Whalen" />
<meta name="DC.Contributor" content="J J Miceli" />
<meta name="DC.Contributor" content="D Tweedie" />
<meta name="DC.Date" content="2000 Jan" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2000.00151.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015052/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC2015052/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC2015052/pdf/bcp0049-035S.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC49CA6FE7C8810000000000D0E2C7" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/151586/">v.49(Suppl 1); 2000 Jan</a></li>
<li class="accid">PMC2015052</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2000 Jan; 49(Suppl 1):
35S–42S.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2000.00151.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2000.00151.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC2015052</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Identification of the major human liver
cytochrome P450 isoform(s) responsible for the formation of the
primary metabolites of ziprasidone and prediction of possible drug
interactions</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Prakash%20C%5Bauth%5D">C Prakash</a>,<sup>1</sup>
<a href="/pubmed/?term=Kamel%20A%5Bauth%5D">A
Kamel</a>,<sup>1</sup> <a href="/pubmed/?term=Cui%20D%5Bauth%5D">D
Cui</a>,<sup>1</sup> <a href=
"/pubmed/?term=Whalen%20RD%5Bauth%5D">R D Whalen</a>, <a href=
"/pubmed/?term=Miceli%20JJ%5Bauth%5D">J J Miceli</a>,<sup>2</sup>
and <a href="/pubmed/?term=Tweedie%20D%5Bauth%5D">D
Tweedie</a><sup>1</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id745411_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>Departments of Drug
Metabolism, Pfizer Central Research, Groton, CT 06340, USA</div>
<div class="fm-affl" lang="en"><sup>2</sup>Clinical Research,
Pfizer Central Research, Groton, CT 06340, USA</div>
<div id="cor1"><em>Correspondence:</em> Dr C. Prakash, Department
of Drug Metabolism, Pfizer Central Research Division, Groton, CT
06340, USA.</div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id745411_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id745411_cpl">Copyright and License
information <span>►</span></a></div>
<div class="fm-article-notes fm-panel half_rhythm"></div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id745411_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2000 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC2015052/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid401656" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid401656title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To identify the cytochrome P450
(CYP) isoform(s) responsible for the formation of the primary
metabolite of ziprasidone (ziprasidone sulphoxide), to determine
the kinetics of its formation and to predict possible drug
interactions by investigating CYP isoform inhibition in an <em>in
vitro</em> study.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last"><em>In vitro</em> metabolism of
[<sup>14</sup>C]-ziprasidone was studied using human liver
microsomes. The metabolites were identified using mass
spectrometry. The kinetics of metabolite formation were determined
using [<sup>14</sup>C]-ziprasidone (10–200 μ<span class=
"small-caps">m</span>) over 5 min, and
<em>K</em><sub><em>m</em></sub> and <em>V</em><sub>max</sub> were
estimated from Lineweaver-Burk plots. I<em>C</em><sub>50</sub>
values for the inhibition of specific probe substrates for CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4, by ziprasidone, risperidone and
9-hydroxyrisperidone were also determined using human liver
microsomes from three subjects. Mean <em>K</em><sub>i</sub> values
were calculated.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">Three CYP-mediated metabolites
– ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic
acid – were identified. The apparent
<em>K</em><sub><em>m</em></sub> and <em>V</em><sub>max</sub> values
for the formation of the major metabolite, ziprasidone sulphoxide
(measured as the sum of sulphoxide and sulphone) were 235
μ<span class="small-caps">m</span> and 1.14 nmol mg<sup>−1</sup>
protein min<sup>−1</sup>, respectively. Isoform-selective
inhibitors and recombinant enzymes indicated that CYP3A4 is
responsible for the formation of ziprasidone metabolites.
Ziprasidone was not a substrate for the other isoforms studied.
Similar <em>in vitro</em> inhibition of CYP2D6
(<em>K</em><sub>i</sub> 6.9–16 μ<span class="small-caps">m</span>)
and CYP3A4 (<em>K</em><sub>i</sub> 64–80 μ<span class=
"small-caps">m</span>) was obtained with ziprasidone, risperidone
and 9-hydroxyrisperidone. The <em>in vivo</em> free drug
concentrations associated with clinically effective doses of
ziprasidone are at least 1500-fold lower than the mean
<em>K</em><sub>i</sub> for either CYP2D6 inhibition or CYP3A4
inhibition.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">Ziprasidone is predominantly
metabolized by CYP3A4 in human liver microsomes and is not expected
to mediate drug interactions with coadministered CYP substrates, at
clinically effective doses.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">cytochrome P450, drug interactions, enzyme
kinetics, human liver microsomes, ziprasidone</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">The primary oxidative metabolites in
normal human volunteers, following a single 20 mg oral dose of
radiolabelled ziprasidone, were identified as ziprasidone
sulphoxide, ziprasidone sulphone, benzisothiazole piperazine (BITP)
and oxindole acetic acid. These metabolites were also detected
following <em>in vitro</em> incubation of ziprasidone with human
liver microsomes [<a href="#b1" rid="b1" class=
" bibr popnode">1</a>]. Cytochromes P450 (CYP) are involved in the
oxidative metabolism of many drugs, environmental pollutants,
procarcinogens and other xenobiotics [<a href="#b2" rid="b2" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_311012464">2</a>,
<a href="#b3" rid="b3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012460">3</a>]. Changes in the CYP-dependent metabolism
of a particular drug may occur when a co-administered drug acts as
an inducer or inhibitor of the same CYP isoform. This can alter the
systemic exposure of the drug and thereby affect its
pharmacological activity. To characterize and predict possible drug
interactions in humans, it is important to determine which CYPs are
involved in the oxidative metabolism of a new drug [<a href="#b4"
rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012469">4</a>–<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012455">7</a>].</p>
<p id="__p6" class="p p-last">This report presents the results of
<em>in vitro</em> studies which aimed to: (1) identify the CYP
isoforms responsible for the formation of the primary metabolite of
ziprasidone (ziprasidone sulphoxide); (2) elucidate the kinetics of
ziprasidone sulphoxide formation following incubation of
ziprasidone with human liver microsomes; and (3) predict possible
drug–drug interactions by determining <em>K</em><sub>i</sub> values
for <em>in vitro</em> inhibition of the major human CYP
isoforms.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Chemicals</h3>
<p id="__p7" class="p p-first">Ziprasidone:
5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazin-1-yl}ethyl]-6-chloro-1,3-dihydro-2H-indole-2-one
hydrochloride hydrate (<a href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
[<sup>14</sup>C]-Ziprasidone: ziprasidone labelled at the C-2
carbon of the ethyl side chain attached to the piperazine (<a href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
[<sup>3</sup>H]-Ziprasidone: ziprasidone labelled at the C-7
position of the benzisothiazole ring (<a href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
Ziprasidone sulphoxide:
6-chloro-5-(2-[4-(1-oxo-1,2-benzisothiazol-3-yl)-piperazin-1-yl]ethyl)-1,3-dihydro-2H-indole-2-one
(<a href="/pmc/articles/PMC2015052/figure/fig01/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
Ziprasidone sulphone:
6-chloro-5-(2-[4-(1,1-dioxo-1,2-benzisothiazol-3-yl)-piperazin-1-yl]ethyl)-1,3-dihydro-2H-indole-2-one
(<a href="/pmc/articles/PMC2015052/figure/fig01/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
Oxindole acetic acid:
(6-chloro-2-oxo-2,3-dihydro-1H-indol-5-yl)acetic acid (<a href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
BITP: 1,2-{benzisothiazole-3-yl}-1-piperazine (<a href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
[<sup>14</sup>C]-CP-118, 954 (internal standard):
5,7-dihydro-3-[2–1-(phenylmethyl)ethyl]-6H-pyrolo [4,
5-f]1,2-benzisoxazol-6-one. The compounds listed above were
prepared at Pfizer Central Research, Groton, CT, USA, using
published procedures [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_311012463">8</a>,
<a href="#b9" rid="b9" class=" bibr popnode">9</a>].
NADP<sup>+</sup>, (±)-isocitric acid, isocitric dehydrogenase,
1-aminobenzotriazole (ABT) and quinidine were purchased from Sigma
Chemical Co. (St Louis, MO, USA). Ketoconazole was obtained from
Research Diagnostics Inc. (Flanders, NJ, USA). Sulphaphenazole was
obtained from Ultrafine Chemicals (Salford, Manchester, UK).
Furafylline was obtained from Research Biochemicals Inc. (Natick,
MA, USA). All other reagents and solvents were of analytical
grade.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Major <em>in vitro</em> metabolic pathways of
ziprasidone by human liver microsomes.</span></div>
</div>
</div>
</div>
<div id="__sec8" class="sec">
<h3>Preparation of microsomes</h3>
<p id="__p9" class="p p-first">Human liver samples were obtained
from organ donors. Liver and microsome samples were stored at
−70<sup>o</sup>C until used. Microsomes and liver homogenates (S-9)
were prepared by differential centrifugation using standard
procedures [<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012454">10</a>]. Protein concentrations were measured by
the bicinchoninic acid assay [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012456">11</a>] using crystalline bovine serum albumin as
standard and CYP concentrations were determined by the method of
Omura and Sato [<a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012467">12</a>]. Each microsomal preparation was
characterized for five major drug metabolizing CYP isoforms:
CYP1A2; CYP2C9; CYP2C19; CYP2D6 and CYP3A4. The activities of
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 were assessed using
phenacetin [<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012462">13</a>], tolbutamide [<a href="#b14" rid="b14"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_345656305">14</a>], S-mephenytoin [<a href="#b15" rid="b15"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012452">15</a>], bufuralol [<a href="#b16" rid="b16"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012470">16</a>], and testosterone [<a href="#b17" rid=
"b17" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012468">17</a>], respectively, as probe substrates.</p>
<p id="__p10" class="p p-last">Microsomes prepared from human
B-lymphoblastoid cells, containing cDNA-expressed CYP1A2 were
purchased from Gentest Corporation (Woburn, MA, USA). Recombinant
CYPs expressed in insect cells (CYP2C9, CYP2C19, CYP2D6 and CYP3A4)
were generated in the Molecular Sciences Department at Pfizer Inc.
and microsomal subcellular fractions were prepared by standard
centrifugation procedures [<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012465">10</a>]. The activities of expressed CYP1A2
(7-ethoxyresorufin deethylation), CYP2C9 (tolbutamide
hydroxylation), CYP2C19 (S-mephenytoin hydroxylation), CYP2D6
(bufuralol 1′-hydroxylation), and CYP3A4 (testosterone
6-β-hydroxylation), were 0.1, 1.8, 0.11, 0.91, and 9.0 nmol
mg<sup>−1</sup> microsomal protein min<sup>−1</sup>,
respectively.</p>
</div>
<div id="__sec9" class="sec">
<h3>Incubations</h3>
<p id="__p11" class="p p-first-last">The incubation mixture (final
volume 1 ml) contained liver microsomes (0.5 μ<span class=
"small-caps">m</span> CYP), [<sup>14</sup>C]-ziprasidone (50
μ<span class="small-caps">m</span>, 0.2% DMSO), 100 m<span class=
"small-caps">m</span> potassium phosphate buffer (pH 7.4) and an
NADPH-generating system (9 m<span class="small-caps">m</span>
MgCl<sub>2</sub>, 0.54 m<span class="small-caps">m</span>
NADP<sup>+</sup>, 6.2 m<span class="small-caps">m</span>
(±)-isocitric acid, and 0.5 U ml<sup>−1</sup> isocitric
dehydrogenase). The reactions were initiated by addition of an
NADPH regenerating system after a 5 min preincubation period.
Reactions were incubated at 37<sup>o</sup>C for 30 min and were
stopped by the addition of methanol (2 ml). Incubations with S-9
fraction contained protein equivalent to 32 mg ml<sup>−1</sup> of
liver and incubations with recombinant CYP contained 1 mg
ml<sup>−1</sup> of microsomal protein.</p>
</div>
<div id="__sec10" class="sec">
<h3>Time course for metabolite formation</h3>
<p id="__p12" class="p p-first-last">The time course of ziprasidone
sulphone and ziprasidone sulphoxide metabolite formation with human
liver microsomes was studied at 10 μ<span class=
"small-caps">m</span> and 100 μ<span class="small-caps">m</span>
concentrations of [<sup>14</sup>C]-ziprasidone. Reactions were
carried out as described above, were terminated at 0, 5, 15, 30,
45, and 60 min, and analysed by high pressure liquid chromatography
(h.p.l.c.) using a radioactivity monitor (described below).</p>
</div>
<div id="__sec11" class="sec">
<h3>Kinetics of ziprasidone metabolism</h3>
<p id="__p13" class="p p-first-last">Nine concentrations of
[<sup>14</sup>C]-ziprasidone, ranging from 10 to 200 μ<span class=
"small-caps">m</span>, were studied in the kinetic experiments
using human liver (HL-1011) microsomes. Incubations were carried
out for 5 min. Reaction rates were linear with respect to protein
concentration and time of incubation. Apparent
<em>K</em><sub><em>m</em></sub> and <em>V</em><sub>max</sub> values
for the formation of ziprasidone sulphoxide (sum of ziprasidone
sulphoxide and ziprasidone sulphone) were estimated from
Lineweaver-Burk plots using linear regression analysis [<a href=
"#b18" rid="b18" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012459">18</a>].</p>
</div>
<div id="__sec12" class="sec">
<h3>Correlation studies</h3>
<p id="__p14" class="p p-first-last">Formation rates of ziprasidone
sulphoxide and sulphone were also measured using microsomes from
eight different human livers (HL-H5, HL-H6–2, HL-1003–3, HL-1008,
HL-1009, HL-1011, HL-1013, HL-1014) at a substrate concentration of
50 μ<span class="small-caps">m</span> as described above. Formation
rates were correlated with activities of isoform-selective probe
substrates to assess the possible involvement of individual
isoforms.</p>
</div>
<div id="__sec13" class="sec">
<h3>Inhibition studies</h3>
<p id="__p15" class="p p-first-last">Inhibitors of CYP3A4,
ketoconazole (10 μ<span class="small-caps">m</span>); CYP2C9,
sulphaphenazole (50 μ<span class="small-caps">m</span>); CYP1A2,
furafylline (20 μ<span class="small-caps">m</span>); CYP2D6,
quinidine (5 μ<span class="small-caps">m</span>) and a general
inhibitor of CYP, 1-aminobenzotriazole (ABT, 5 m<span class=
"small-caps">m</span>) were incubated with
[<sup>14</sup>C]-ziprasidone and S-9. The inhibitors were dissolved
in water or methanol. The concentration of organic solvent in the
incubates was maintained at no greater that 0.5% of the incubation
volume to avoid an effect of solvent on metabolism. Incubations
were performed in duplicate and the pairs of resulting values
averaged.</p>
</div>
<div id="__sec14" class="sec">
<h3>Quantification of metabolites formed with human liver
microsomes</h3>
<p id="__p16" class="p p-first">[<sup>14</sup>C]-ziprasidone
metabolites formed in microsomal incubations (described above) were
quantified by h.p.l.c. with radioactivity monitoring (β-RAM). A 100
μl aliquot of internal standard (IS) [<sup>14</sup>C]-CP-118, 954
(0.01 mg ml<sup>−1</sup>) was added to the terminated reaction and
the mixture was evaporated to dryness on a Speed-Vac evaporator.
The residue was reconstituted in 300 μl of mobile phase (described
below; solvent A: solvent B, 50:50, v/v), sonicated and centrifuged
to remove protein. A 60 μl portion of the supernatant was analysed
by h.p.l.c. A standard curve was constructed by plotting the peak
area (counts min<sup>−1</sup>) ratio of
[<sup>14</sup>C]-ziprasidone to IS against the concentration of
[<sup>14</sup>C]-ziprasidone added to the mixture. Unknown
concentrations of metabolites were estimated by interpolation from
the standard curve.</p>
<p id="__p17" class="p p-last">The h.p.l.c. system consisted of a
Rheodyne injector, LDC/Milton Roy constametric CM4000 gradient
pump, Waters Lambda-Max model 481 u.v. detector, radioactivity
monitor (β-RAM) and an SP 4200 computing integrator. Chromatography
was carried out on a YMC basic h.p.l.c. column (4.6 mm× 250 mm, 5
μ<span class="small-caps">m</span>) with a binary mixture of
methanol (solvent A) and 20 m<span class="small-caps">m</span>
ammonium acetate (pH 5.0, solvent B). The mobile phase initially
consisted of solvent A: solvent B (30:70, v/v) for 5 min, which was
then linearly programmed to a solvent ratio of 50:50 over 35 min,
maintained for 1 min and then linearly increased to a ratio of
90:10 over 9 min. The system was allowed to re-equilibrate for
approximately 10 min before making the next injection. Retention
times of metabolites were compared with those of synthetic
standards to confirm identity.</p>
</div>
<div id="__sec15" class="sec sec-last">
<h3>Inhibition of isoform-selective substrates by ziprasidone,
risperidone and 9-hydroxyrisperidone</h3>
<p id="__p18" class="p p-first-last">I<em>C</em><sub>50</sub>
values (50% inhibition of the activity observed in the absence of
the inhibitor) for the inhibition of probe substrates specific for
the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, by
ziprasidone, risperidone and 9-hydroxyrisperidone, were determined
using individual preparations of human liver microsomes from three
subjects. Incubate concentrations of ziprasidone, risperidone and
9-hydroxyrisperidone ranged from 0.1 μm to 100 μm. Final incubate
concentrations of the solvent DMSO were kept constant at 0.2%
(v/v). Probe substrate concentrations were 20 μm for phenacetin,
200 μm for tolbutamide, 100 μm for S-mephenytoin, 10 μm for
bufuralol and 20 μm for testosterone. I<em>C</em><sub>50</sub>
values &lt; 100 μm were determined using the equation Y = 100
–[100X/(X+ B)], where X=inhibitor concentration and B=
I<em>C</em><sub>50</sub> value. <em>K</em><sub>i</sub> values were
experimentally determined for interactions with CYP2D6 by Dixon
plot. Bufuralol concentrations were 5, 10, and 20 μm, and inhibitor
concentrations were 0, 5, 10, and 20 μm. Individual
<em>K</em><sub>i</sub> values were calculated as the mean of each
intercept. <em>K</em><sub>i</sub> values for the interaction with
CYP3A4 were calculated from I<em>C</em><sub>50</sub> values using
the equation I<em>C</em><sub>50</sub>=
(1+[S]/<em>K</em><sub><em>m</em></sub>)<em>K</em><sub>i</sub> as
defined by Segel [<a href="#b19" rid="b19" class=
" bibr popnode">19</a>] for a competitive inhibitor.</p>
</div>
</div>
<div id="__sec16" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec16title">Results</h2>
<div id="__sec17" class="sec sec-first">
<h3>CYP-dependent metabolism of ziprasidone</h3>
<p id="__p19" class="p p-first">A representative chromatogram of
the supernatant following incubation of
[<sup>14</sup>C]-ziprasidone with human liver microsomes is shown
in <a href="/pmc/articles/PMC2015052/figure/fig02/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>. As
seen in Figure 2, five radioactive peaks were observed in
microsomal incubations. Only three peaks with retention times of
20.5, 39.6 and 40.5 min, were identified by mass spectrometry as
oxindole acetic acid (M4), ziprasidone sulphone (M8) and
ziprasidone sulphoxide (M10), respectively. These structures were
confirmed by comparing respective retention times with synthetic
standards onh.p.l.c. [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012471">8</a>]. Metabolite formation was NADPH-dependent
and was largely abolished in the presence of 1-aminobenzotriazole
(ABT, 5 mm) indicating that CYP was responsible (data not
shown).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015052/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>H.p.l.c. radiochromatograms of metabolites of
ziprasidone in human liver microsomes. M4: oxindole acetic acid;
M8: ziprasidone sulphone; M10: ziprasidone sulphoxide.</span></div>
</div>
</div>
</div>
<div id="__sec18" class="sec">
<h3>Time course for the formation of metabolites</h3>
<p id="__p21" class="p p-first">The time course for the combined
formation of ziprasidone sulphoxide and ziprasidone sulphone
metabolites at two ziprasidone concentrations (10 μm and 100 μm) is
shown in <a href="/pmc/articles/PMC2015052/figure/fig03/" target=
"figure" class="fig-table-link fig figpopup" rid-figpopup="fig03"
rid-ob="ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure
3</span></a>. Formation rates of the two metabolites were linear
for the first 5 min.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015052/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>Time course for the formation of ziprasidone sulphoxide
and sulphone at a concentration of 10 µ<span class=
"small-caps">m</span> (a) and 100 µ<span class=
"small-caps">m</span> (b).</span></div>
</div>
</div>
</div>
<div id="__sec19" class="sec">
<h3>Kinetics of the formation of metabolites</h3>
<p id="__p23" class="p p-first">A typical reaction
velocity/substrate concentration curve for the combined formation
of the metabolites, ziprasidone sulphoxide and ziprasidone
sulphone, is shown in <a href=
"/pmc/articles/PMC2015052/figure/fig04/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig04" rid-ob=
"ob-fig04" co-legend-rid="lgnd_fig04"><span>Figure 4</span></a>.
The apparent <em>V</em><sub>max</sub> and
<em>K</em><sub><em>m</em></sub> values for the formation of
ziprasidone sulphoxide (sum of sulphoxide and sulphone) were
calculated as 1.14 nmol mg<sup>−1</sup> protein min<sup>−1</sup>
and 235 μm, respectively, which represents an intrinsic clearance
value of 0.0048 ml mg<sup>−1</sup> protein min<sup>−1</sup>.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig04"
co-legend-rid="lgnd_fig04"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015052/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04"><img src=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f4.gif" class=
"small-thumb" alt="Figure 4" title="Figure 4" src-large=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f4.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig04">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04">Figure 4</a></div>
<!--caption a4-->
<div><span>Typical velocity/concentration (Michaelis-Menten) plot
for the formation of ziprasidone sulphoxide (measured as combined
sulphoxide and sulphone) by human liver microsomes.</span></div>
</div>
</div>
</div>
<div id="__sec20" class="sec">
<h3>Correlation studies</h3>
<p id="__p25" class="p p-first">Rates of formation of ziprasidone
sulphoxide (sum of sulphoxide and sulphone) with liver microsomes
from eight human individuals were measured at a substrate
concentration of 50 μm. Formation of ziprasidone sulphoxide (sum of
sulphoxide and sulphone) correlated (<em>r</em> = 0.83)
significantly with testosterone 6-β-hydroxylation activity (CYP3A4,
<a href="/pmc/articles/PMC2015052/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). The formation
of ziprasidone sulphoxide (sum of sulphoxide and sulphone) also
correlated (<em>r</em> =0.70) with S-mephenytoin hydroxylase
activity (CYP2C19). No significant correlations were found between
the sulphoxidation of ziprasidone and the other CYP specific
substrates.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC2015052/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC2015052/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC2015052/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Correlation of various CYP isoform-selective
monoxygenase activities with the sulphoxidation
(sulphoxide+sulphone) of ziprasidone in human liver
microsomes.</span></div>
</div>
</div>
</div>
<div id="__sec21" class="sec">
<h3>Inhibition studies</h3>
<p id="__p28" class="p p-first">Inhibition of metabolite formation
by each inhibitor is summarized in <a href=
"/pmc/articles/PMC2015052/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>. Ketoconazole
(10 μm) inhibited the formation of ziprasidone sulphoxide
(sulphoxide and sulphone) by 79% and oxindole acetic acid
(<em>N</em>-dealkylated product) completely. Sulphaphenazole and
furafylline did not inhibit the formation of ziprasidone
sulphoxide. The formation of oxindole acetic acid was inhibited
(∼50%) by furafylline. The formation of ziprasidone metabolites was
not inhibited by quinidine but rather increased.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC2015052/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC2015052/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC2015052/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span>Effects of isoform-specific inhibitors of human CYP on
the metabolism of ziprasidone.</span></div>
</div>
</div>
</div>
<div id="__sec22" class="sec">
<h3>Metabolism by recombinant CYP isoforms</h3>
<p id="__p34" class="p p-first">The ability of specific CYP
isoforms to metabolize ziprasidone was determined using recombinant
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity
profiles of ziprasidone metabolites following incubation of
[<sup>14</sup>C]-ziprasidone or [<sup>3</sup>H]-ziprasidone with
CYP3A4 are shown in <a href=
"/pmc/articles/PMC2015052/figure/fig05/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig05" rid-ob=
"ob-fig05" co-legend-rid="lgnd_fig05"><span>Figure 5(a) and
(b)</span></a>, respectively. CYP3A4 catalysed the formation of the
<em>N</em>-dealkylated metabolite (M5), as well as ziprasidone
sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative
metabolites were not detected in incubations containing recombinant
CYP1A2, CYP2C9, CYP2C19 or CYP2D6. As the enzyme activities of the
recombinant CYPs were selected to reflect activities typical of a
human liver microsomal preparation (see Methods), it can be
concluded that these latter isoforms do not contribute
significantly to ziprasidone metabolism.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig05"
co-legend-rid="lgnd_fig05"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015052/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05"><img src=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f5.gif" class=
"small-thumb" alt="Figure 5" title="Figure 5" src-large=
"/pmc/articles/PMC2015052/bin/bcp0049-035S-f5.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig05">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05">Figure 5</a></div>
<!--caption a4-->
<div><span>H.p.l.c. radiochromatograms of metabolites of
[<sup>14</sup>C]-ziprasidone (a) and [<sup>3</sup>H]-ziprasidone
(b) by recombinant CYP3A4. M8: ziprasidone sulphone; M10:
ziprasidone sulphoxide.</span></div>
</div>
</div>
</div>
<div id="__sec23" class="sec sec-last">
<h3><em>In vitro</em> inhibition of CYP isoforms by
ziprasidone</h3>
<p id="__p36" class="p p-first">Interactions with CYP2D6 exhibited
the lowest mean I<em>C</em><sub>50</sub> values of 31 μm for
ziprasidone, 14 μm for risperidone, and 31 μm for
9-hydroxyrisperidone (<a href=
"/pmc/articles/PMC2015052/table/tbl3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob=
"ob-tbl3" co-legend-rid=""><span>Table 3</span></a>).
I<em>C</em><sub>50</sub> values for interaction with CYP3A4 were
higher at 72, 75 and 90 μm, respectively. All of the other
I<em>C</em><sub>50</sub> values were greater than 100 μm except
that for the interaction between 9-hydroxyrisperidone and CYP2C19
(52 μm). Mean <em>K</em><sub>i</sub> values for interaction with
CYP2D6 were similar for all three compounds; 11 μm for ziprasidone,
6.9 μm for risperidone and 16 μm for 9-hydroxyrisperidone (<a href=
"/pmc/articles/PMC2015052/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Mean
<em>K</em><sub>i</sub> values for interaction with CYP3A4 were
calculated from I<em>C</em><sub>50</sub> values assuming
competitive inhibition and an average
<em>K</em><sub><em>m</em></sub> value of 100 μm. These were 64 μm
for ziprasidone, 67 μm for risperidone, and 80 μm for
9-hydroxyrisperidone.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl4"><a href="/pmc/articles/PMC2015052/table/tbl4/" target=
"table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class=
"table img_link icnblk_img figpopup"><img alt="Table 4" title=
"Table 4" class="small-thumb" src=
"/pmc/articles/PMC2015052/table/tbl4/?report=thumb" src-large=
"/pmc/articles/PMC2015052/table/tbl4/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/table/tbl4/" target="table" rid-figpopup=
"tbl4" rid-ob="ob-tbl4">Table 4</a></div>
<!--caption a4-->
<div><span><em>K</em><sub>i</sub> values for inhibition of
bufuralol 1′-hydroxylase activity (CYP2D6) by ziprasidone,
risperidone, and 9-hydroxyrisperidone.<sup>a</sup></span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl3"><a href="/pmc/articles/PMC2015052/table/tbl3/" target=
"table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class=
"table img_link icnblk_img figpopup"><img alt="Table 3" title=
"Table 3" class="small-thumb" src=
"/pmc/articles/PMC2015052/table/tbl3/?report=thumb" src-large=
"/pmc/articles/PMC2015052/table/tbl3/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015052/table/tbl3/" target="table" rid-figpopup=
"tbl3" rid-ob="ob-tbl3">Table 3</a></div>
<!--caption a4-->
<div><span>Interaction of ziprasidone, risperidone and
9-hydroxyrisperidone with human liver cytochromes P450:
I<em>C</em><sub>50</sub>values for inhibition of probe substrate
activities.</span></div>
</div>
</div>
</div>
</div>
<div id="__sec24" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec24title">Discussion</h2>
<p id="__p45" class="p p-first">The present work describes the
<em>in vitro</em> metabolism of ziprasidone using human liver
microsomes, S-9 and recombinant human CYP isoforms. The oxidative
metabolites produced from ziprasidone by human liver microsomes
were ziprasidone sulphoxide, ziprasidone sulphone, oxindole acetic
acid and BITP. These metabolites were excreted <em>in
vivo</em>[<a href="#b20" rid="b20" class=" bibr popnode">20</a>].
Ziprasidone sulphoxide and sulphone were the major circulating
metabolites in all species [<a href="#b20" rid="b20" class=
" bibr popnode">20</a>–<a href="#b22" rid="b22" class=
" bibr popnode">22</a>]. Kinetic analysis of ziprasidone sulphoxide
formation (measured as the sum of sulphoxide and sulphone) produced
a monophasic Lineweaver-Burk plot suggesting that a single CYP
isoform was responsible for sulphoxide formation. Based on CYP
isoform-selective chemical inhibitors, correlation studies and
metabolism by recombinant human CYP enzymes, the work presented
here demonstrates that human liver CYP3A4 has a major role in the
oxidative metabolism of ziprasidone.</p>
<p id="__p46">Ketoconazole, a selective inhibitor of CYP3A4
[<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012458">23</a>], markedly inhibited the formation of the
major metabolites of ziprasidone. The formation of ziprasidone
sulphoxide (sum of ziprasidone sulphoxide and ziprasidone sulphone)
significantly correlated with CYP3A4 and CYP2C19 specific
monooxygenase activities, whereas no correlation was observed
between ziprasidone metabolite formation and bufuralol
1′-hydroxylation (CYP2D6), 7-ethoxyresorufin de-ethylation
(CYP1A2), or tolbutamide hydroxylation (CYP2C9). The formation of
ziprasidone sulphoxide and sulphone correlated with CYP2C19
activity (<em>r</em> = 0.70) but these metabolites were not
detected following incubation of [<sup>14</sup>C]-ziprasidone with
recombinant CYP2C19. As the probe substrate activities of CYP2C19
correlated with CYP3A4 (<em>r</em> = 0.52), this correlation may be
fortuitous, indicating that CYP2C19 was probably not involved in
the formation of ziprasidone sulphoxide and sulphone. Whilst CYP3A4
is primarily responsible for ziprasidone metabolism in human liver
microsomes, studies in healthy men have shown that cimetidine (a
CYP3A4 inhibitor) does not affect ziprasidone metabolism [<a href=
"#b24" rid="b24" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012466">24</a>].</p>
<p id="__p47">Consistent with the results obtained from correlation
and inhibition studies, microsomes containing human recombinant
CYP3A4 catalysed the conversion of [<sup>14</sup>C]-ziprasidone to
ziprasidone sulphoxide and ziprasidone sulphone and
[<sup>3</sup>H]-ziprasidone to BITP, ziprasidone sulphoxide and
ziprasidone sulphone. The <em>N</em>-dealkylated metabolite,
oxindole acetic acid, was not detected following incubation of
[<sup>14</sup>C]-ziprasidone with CYP3A4. <em>N</em>-dealkylation
involves initial hydrogen abstraction with subsequent hydroxylation
at an alpha carbon to form an unstable carbinolamine intermediate.
This intermediate then decomposes to form an aldehyde which can be
oxidized by aldehyde oxidase or CYP to form an acid metabolite
[<a href="#b25" rid="b25" class=" bibr popnode">25</a>]. It is
possible that oxindole acetaldehyde was formed following incubation
of [<sup>14</sup>C]-ziprasidone with CYP3A4. However, no attempt to
identify the aldehyde intermediate could be made because a
synthetic standard was not available. As the <sup>14</sup>C label
was located on the C-2 carbon of the ethyl side chain attached to
the piperazine, the counterpart of the <em>N</em>-dealkylated
product, BITP, could not be detected either. The formation of BITP
was confirmed by incubating [<sup>3</sup>H]-ziprasidone, labelled
at the C-7 position of the benzisothiazole, with recombinant
CYP3A4.</p>
<p id="__p48">The interaction of ziprasidone, risperidone and the
major <em>in vivo</em> metabolite of risperidone,
9-hydroxyrisperidone, with human CYPs was determined by
investigating the ability of these compounds to inhibit the
metabolism of isoform-specific metabolic pathways for each of the
five major human hepatic drug-metabolizing CYPs; CYP1A2, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4. The most potent interaction was
observed with CYP2D6. Similar mean <em>K</em><sub>i</sub> values of
11, 6.9 and 16 μm were obtained for inhibition of CYP2D6-mediated
bufuralol 1-hydroxylation by ziprasidone, risperidone, and
9-hydroxyrisperidone, respectively. As demonstrated in this report,
ziprasidone is not a substrate for CYP2D6 but does bind as a
potential inhibitor. On the other hand, risperidone demonstrates a
polymorphic metabolism typical of a CYP2D6 substrate [<a href=
"#b26" rid="b26" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012461">26</a>], an interaction which is consistent with
the low <em>K</em><sub>i</sub> value observed in this study. A
weaker interaction with CYP3A4 was observed for each of these
compounds, with <em>K</em><sub>i</sub> values ranging from 3- to
10-fold higher than for CYP2D6. I<em>C</em><sub>50</sub> values for
all other interactions were generally greater than 100 μm and were
considered not to be clinically significant.</p>
<p id="__p49">At the upper end of the therapeutic dose range for
ziprasidone (80 mg twice daily), the mean serum
<em>C</em><sub>max</sub> achieved in humans is approximately 326 ng
ml<sup>−1</sup>. Plasma protein binding of ziprasidone has been
determined in a clinical study to range from 99.65 to 99.94%[T.
Smolarek, personal communication]. Considering only the higher free
fraction value, an unbound drug <em>C</em><sub>max</sub> was
calculated, which is equivalent to a free drug
<em>C</em><sub>max</sub> of 0.007 μm. To determine the potential
for <em>in vivo</em> drug interactions, this serum
<em>C</em><sub>max</sub> is compared with the <em>in vitro</em>
inhibition constant, <em>K</em><sub>i</sub>. At the therapeutic
dose, the free drug concentration of ziprasidone is approximately
1500-fold lower than the mean <em>K</em><sub>i</sub> exhibited for
CYP2D6 and more than 9000-fold lower than the mean
<em>K</em><sub>i</sub> calculated for CYP3A4. Thus, ziprasidone is
not expected to affect significantly the metabolism of
coadministered drugs that are metabolized by these isoforms.
Interactions with the other major drug-metabolizing CYP isoforms
were less potent and therefore drug interactions with these
isoforms are less likely.</p>
<p id="__p50">Estimated steady-state plasma concentrations for
risperidone and its active metabolite, 9-hydroxyrisperidone, in
schizophrenic patients receiving risperidone, 8 mg twice daily,
were approximately 20 and 110 ng ml<sup>-1</sup>, respectively
[<a href="#b27" rid="b27" class=" bibr popnode">27</a>]. Assuming a
peak-to-trough ratio of 5 for risperidone (<em>t</em><sub>½,z</sub>
of 3 h in extensive metabolisers) and a peak-to-trough ratio of 1
for its metabolite (<em>t</em><sub>½,z</sub> of 20 h), the
anticipated steady-state <em>C</em><sub>max</sub> concentrations
for risperidone and its metabolite would be 100 and 110 ng
ml<sup>−1</sup>, respectively. The unbound (fraction unbound of
0.1) and total plasma <em>C</em><sub>max</sub> for risperidone
would then be 0.024 and 0.24 μm, respectively. These concentrations
are 300- and 30-fold lower than their respective
<em>K</em><sub>i</sub> values for CYP2D6. Thus, although the
unbound <em>C</em><sub>max</sub> for risperidone is greater than
that for ziprasidone, based on our best estimates of therapeutic
concentrations of risperidone at clinically efficacious doses,
inhibition of coadministered substrates for CYP2D6 would also not
be anticipated for risperidone, even with the additional
contribution from its active metabolite, 9-hydroxyrisperidone.</p>
<p id="__p51" class="p p-last">The results of this <em>in
vitro</em> study indicate that ziprasidone can be administered
together with substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4, without the expectation of pharmacokinetic interactions.
Although ziprasidone interacts with CYP2D6 and CYP3A4, it is not
expected to inhibit these isozymes at clinically effective doses.
There is some uncertainty as to the appropriate <em>in vivo</em>
drug concentration with which to compare the <em>in
vitro</em>-derived inhibitory constants [<a href="#b28" rid="b28"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012457">28</a>]. However, even using a conservative
estimate of relevant <em>in vivo</em> concentrations, total
ziprasidone <em>C</em><sub>max</sub>, the anticipated inhibition by
ziprasidone, acting as a competitive inhibitor of CYP2D6, would
only be approximately 4%. The lack of clinically significant
inhibition of CYP2D6 by ziprasidone has been confirmed <em>in
vivo</em> in a study in healthy volunteers. In this study,
treatment with ziprasidone (80 mg) did not change the urinary
dextromethorphan/dextrorphan ratio, an indicator of CYP2D6
activity, whereas treatment with paroxetine (20 mg), which has been
shown to inhibit coadministered substrates of CYP2D6 [<a href=
"#b29" rid="b29" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012472">29</a>], increased the ratio 10-fold [<a href=
"#b30" rid="b30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012453">30</a>].</p>
</div>
<div id="__ackid735507" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid735507title">
Acknowledgments</h2>
<div class="sec">
<p id="__p52">We would like to thank Dr Keith McCarthy and Ms
Cynthia Morrency for synthesizing radiolabelled ziprasidone, Dr
Larry Tremaine for helpful suggestions and Ms Dayna Mankowski for
technical assistance.</p>
</div>
</div>
<div id="__ref-listid735515" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid735515title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"element-citation">Kamel A, Prakash C. Identification of <em>in
vitro</em> metabolites of CP-88,059 in humans: characterization of
metabolites by LC-MS/MS. Proceedings of the 43rd ASMS Conference on
Mass Spectrometry and Allied Topics 887.</span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"element-citation">Nelson DR, Kamataki T, Waxman DJ, et al. The
P450 superfamily: update on new sequences, gene mapping, accession
numbers, early trivial names and nomenclature. <span><span class=
"ref-journal">DNA Cell Biol.</span> 1993;<span class=
"ref-vol">12</span>:1–51.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7678494" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"element-citation">Gonzalez FJ. The molecular biology of cytochrome
P450s. <span><span class="ref-journal">Pharmacol Rev.</span>
1989;<span class="ref-vol">40</span>:243–288.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3072575" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"element-citation">Peck CC, Temple R, Collins JM. Understanding
consequences of concurrent therapies. <span><span class=
"ref-journal">JAMA.</span> 1993;<span class=
"ref-vol">269</span>:1550–1552.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8445821" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"element-citation">Tucker GT. The rational selection of drug
interaction studies: implications of recent advances in drug
metabolism. <span><span class="ref-journal">Int J Clin Pharmacol
Ther Toxicol.</span> 1992;<span class=
"ref-vol">30</span>:550–553.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1490831" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"element-citation">Wrighton SA, Vandenbranden M, Stevens J, et al.
<em>In vitro</em> methods for assessing human hepatic drug
metabolism: their use in drug development. <span><span class=
"ref-journal">Drug Metab Rev.</span> 1993;<span class=
"ref-vol">25</span>:453–484.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8313838" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"element-citation">Rodriguez AD. Use of <em>in vitro</em>
metabolism studies in drug development. An industrial perspective.
<span><span class="ref-journal">Biochem Pharmacol.</span>
1994;<span class="ref-vol">48</span>:2147–2156.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7811296" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"element-citation">Prakash C, Kamel A, Anderson W, Howard H.
Metabolism and excretion of an antipsychotic drug ziprasidone in
rat following oral administration of a mixture of <sup>14</sup>C
and <sup>3</sup>H labelled ziprasidone. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1997;<span class=
"ref-vol">25</span>:206–218.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9029052" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"element-citation">Howard HR, Shenk KD, Smolarek TA, et al.
Synthesis of 3H- and 14C-labeled CP-88,059: a potent atypical
antipsychotic agent. <span><span class="ref-journal">J Labelled
Compd Radiopharm.</span> 1994;<span class=
"ref-vol">34</span>:117–125.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"element-citation">Tweedie DJ, Burke MD. Differential effects of
phenobarbitone and 3-methylcholanthrene induction on the hepatic
microsomal metabolism of the beta-carbolines harmine and harmol.
<span><span class="ref-journal">Biochem Pharmacol.</span>
1983;<span class="ref-vol">32</span>:653–663.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/6830628" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"element-citation">Smith PK, Krohn RI, Hermanson GT, et al.
Measurement of protein using bicinchoninic acid. <span><span class=
"ref-journal">Anal Biochem.</span> 1985;<span class=
"ref-vol">150</span>:76–85.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3843705" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"element-citation">Omura T, Sato R. The carbon monoxide binding
pigment of liver microsomes, I. Evidence of its hemoprotein nature.
<span><span class="ref-journal">J Biol Chem.</span>
1964;<span class="ref-vol">239</span>:2370–2378.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/14209971" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"element-citation">Tassaneeyakul W, Birkett DJ, Veronese ME, et al.
Specificity of substrate and inhibitor probes for human cytochromes
P450 1A1 and 1A2. <span><span class="ref-journal">J Pharmacol Exp
Ther.</span> 1993;<span class="ref-vol">265</span>:401–407.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/8474022" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"element-citation">Miners JO, Smith KJ, Robson RA, et al.
Tolbutamide hydroxylation by human liver microsomes.
<span><span class="ref-journal">Biochem Pharmacol.</span>
1988;<span class="ref-vol">37</span>:137–144.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3355588" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"element-citation">Meier UT, Kronbach T, Meyer UA. Assay of
mephenytoin metabolism in human liver microsomes by high
performance liquid chromatography. <span><span class=
"ref-journal">Anal Biochem.</span> 1985;<span class=
"ref-vol">151</span>:286–291.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/4096368" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"element-citation">Kronbach T. Bufuralol, dextromethorphan, and
debrisoquine as prototype substrates for human P450IID6.
<span><span class="ref-journal">Meth Enzymol.</span>
1991;<span class="ref-vol">206</span>:509–517.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1686064" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"element-citation">Sonderfan AJ, Arlotto MP, Dutton DR, et al.
Regulation of testosterone hydroxylation by rat liver microsomal
cytochrome P-450. <span><span class="ref-journal">Arch Biochem
Biophys.</span> 1987;<span class="ref-vol">255</span>:27–41.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/3592665" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"element-citation">Orsi BA, Tipton KF. Kinetic analysis of progress
curves. <span><span class="ref-journal">Meth Enzymol.</span>
1979;<span class="ref-vol">63</span>:159–183.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/502859" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"element-citation">Segel IH. <span class="ref-journal">Enzyme
Kinetics: Behaviours and Analysis of Rapid Equilibrium and
Steady-State Enzyme Systems.</span> New York: John Wiley and Sons;
1975. pp. 100–226.</span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"element-citation">Prakash C, Kamel A, Anderson W, Wilner K.
Characterization of metabolites of ziprasidone in human by
LC-MS/MS. Proceedings of the 44th ASMS Conference on Mass
Spectrometry and Allied Topics 563.</span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"element-citation">Prakash C, Kamel A, Anderson W, Fouda H.
Characterization of metabolites of CP-88,059 in rat using
HPLC/RAM/ESI/MS/MS. Proceedings of the 42nd ASMS Conference on Mass
Spectrometry and Allied Topics 355.</span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"element-citation">Prakash C, Kamel A, Anderson W.
Biotransformation of antipsychotic drug ziprasidone in dogs.
Proceedings of the 4th International ISSX Meeting 312.</span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"element-citation">Newton DJ, Wang RW, Lu AY. Cytochrome P450
inhibitors. Evaluation of specificities in the <em>in vitro</em>
metabolism of therapeutic agents by human liver microsomes.
<span><span class="ref-journal">Drug Metab Dispos.</span>
1995;<span class="ref-vol">23</span>:154–158.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7720520" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"element-citation">Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The
pharmacokinetics of ziprasidone in healthy volunteers treated with
cimetidine or antacid. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 2000;<span class="ref-vol">49</span>(Suppl.
1):57S–60S.</span> <span class="nowrap ref pmc">[<a class=
"int-reflink" href="/pmc/articles/PMC2015049/">PMC free
article</a>]</span> <span class="nowrap ref pubmed">[<a href=
"/pubmed/10771455" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"element-citation">Testa B. In: <span class="ref-journal">The
Metabolism of Drugs and Other Xenobiotics.</span> Testa B, Caldwell
J, editors. New York, Academic Press.; pp. 203–234.</span></div>
<div class="ref-cit-blk half_rhythm" id="b26">26. <span class=
"element-citation">Huang ML, Van Peer A, Woestenborghs R, et al.
Pharmacokinetics of the novel antipsychotic agent risperidone and
the prolactin response in healthy subjects. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1993;<span class=
"ref-vol">54</span>:257–268.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7690693" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b27">27. <span class=
"element-citation">Heykants J. The pharmacokinetics of risperidone
in humans. <span><span class="ref-journal">The Ist International
Risperidone Investigators Meeting;</span>
:19–20.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b28">28. <span class=
"element-citation">Ring BJ, Binkley SN, Roskos L, Wrighton SA.
Effect of fluoxetine, norfluoxetine, sertraline and
desmethylsertraline on human CYP3A catalyzed 1(-hydroxy midazolam
formation <em>in vitro</em>. <span><span class="ref-journal">J
Pharmacol Exp Ther.</span> 1995;<span class=
"ref-vol">275</span>:131–135.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8531073" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b29">29. <span class=
"element-citation">Brosen K, Hansen JG, Nielsen KK, Sindrup SH,
Gram LF. Inhibition by paroxetine of desipramine metabolism in
extensive but not in poor metabolizers of sparteine.
<span><span class="ref-journal">Eur J Clin Pharmacol.</span>
1993;<span class="ref-vol">44</span>:349–355.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8513845" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b30">30. <span class=
"element-citation">Wilner KD, Demattos SB, Anziano RJ, Apseloff G,
Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in
healthy extensive metabolisers. <span><span class="ref-journal">Br
J Clin Pharmacol.</span> 2000;<span class=
"ref-vol">49</span>(Suppl. 1):43S–47S.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC2015060/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/10771453" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015052&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC2015052/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC2015052/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC2015052/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC2015052/pdf/bcp0049-035S.pdf">PDF
(135K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC2015052" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015052%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015052%2F&amp;text=Identification%20of%20the%20major%20human%20liver%20cytochrome%20P450%20isoform(s)%20responsible%20for%20the%20formation%20of%20the%20primary%20metabolites%20of%20ziprasidone%20and%20prediction%20of%20possible%20drug%20interactions">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015052%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="10771452" data-aiid="2015052"
data-aid="2015052" data-iid="151586" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC2015052" data-md5=
"6ff276b839cf8b9a3541002b5146cdae"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2015052/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC49CA6FE7D821_0208SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
